Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings
AVIR·Reported May 12, 2026·After market close
Diluted EPS came in at $-0.57 (-42.5% YoY), beat the $-0.60 consensus by $0.03.
Diluted EPS
$-0.57beat by $0.03
Consensus: $-0.60
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Atea Pharmaceuticals, Inc.'s Q1 2026 earnings report.
Atea Pharmaceuticals, Inc. (AVIR) reported Q1 2026 earnings on May 12, 2026 after market close.
Atea Pharmaceuticals, Inc. reported diluted EPS of $-0.57 for Q1 2026.
EPS beat the consensus estimate of $-0.60 by $0.03.
Compared to the same quarter a year prior, diluted EPS declined 42.5% from $-0.40.
You can read the 8-K earnings release (0001193125-26-219507) and the 10-Q periodic report (0001193125-26-219678) directly on SEC EDGAR. The filing index links above go to sec.gov.